Dec 03, 2008
Notice
Kringle Pharma Initiated a Phase 2 Clinical Trial in Norway on ChronSeal, a Recombinant Human HGF-Based Therapy for the Treatment of Skin Ulcers.
Kringle Pharma Initiated a Phase 2 Clinical Trial in Norway on ChronSeal®, a Recombinant Human HGF-Based Therapy for the Treatment of Skin Ulcers.
